A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...
Genome Editing Market Genome Editing Market Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Genome Editing Market - Global ...
Moderna (MRNA) stock hits a 52-week high to extend its YTD rally following back-to-back years of declines. Read more here.
Key market opportunities in the RNA Therapy Clinical Trials sector include an increase in chronic and rare diseases, advancements in delivery technologies like lipid nanoparticles, robust venture ...
Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...
Company to Initiate First-in-Human Phase 1 Clinical Trial in Q2 2026ROCKVILLE, Md.--(BUSINESS WIRE)--#Clinicaltrials--Immunomic Therapeutics, Inc. (“ITI”), a privately held clinical-stage ...
Korro Bio, Inc. ( KRRO) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 1:30 PM EST ...
Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical ...
Increasing paternal age has been linked to elevated health risks for the next generation, including higher risks of obesity ...
Picture CRISPR-Cas9, a gene editing technology, as a GPS-guided scalpel: gRNA directs the Cas9 enzyme, a protein that cuts ...
While healthcare comes to a turning point driven by advances in gene therapy and RNA editing, shifts in US drug-pricing ...
National Institutes of Health funding for the Capital Region, which provides critical money for medical and biotech research, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback